Selexipag - Actelion/Nippon Shinyaku

Drug Profile

Selexipag - Actelion/Nippon Shinyaku

Alternative Names: ACT-293987; NS-304; Uptravi

Latest Information Update: 12 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Shinyaku
  • Developer Actelion Pharmaceuticals; Nippon Shinyaku
  • Class Acetamides; Antihypertensives; Pyrazines; Small molecules; Sulfonamides; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Phase III Arteriosclerosis obliterans; Pulmonary hypertension
  • Phase II Raynaud's disease; Spinal stenosis

Most Recent Events

  • 29 May 2018 Actelion completes a phase III trial for Pulmonary arterial hypertension in Germany and USA (NCT03187678)
  • 18 May 2018 Actelion completes a phase I trial in Healthy volunteers in Belgium (NCT03496506)
  • 09 May 2018 Phase-II clinical trials in Spinal stenosis (unspecified route) (Nippon Shinyaku pipeline, May 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top